• GSK to make chickenpox vaccine in Russia in deal with Nanolek fiercepharma
    September 26, 2019
    The deal comes as GSK continues to see good growth in vaccines, which tallied £1.6 billion ($1.9 million) in Q2, up 26%. That was driven by strong demand for Shingrix in the U.S. after the shingles vaccine won a U.S. CDC recommendation in 2018. 
PharmaSources Customer Service